CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.61B, above the global median of $1.15B
- FinancialsAltman Z-Score 7.4: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.61BUSDvs all stocks (USD)
Revenue (TTM)
535.08MUSDvs all stocks (USD)
Profit Margin
-9.02%vs Biotechnology peers
Beta
0.4990xvs all stocks
52-Week Change
41.89%vs all stocks
Market Capitalization
2.61BUSDvs all stocks (USD)
Enterprise Value
2.27BUSDvs all stocks (USD)
Forward P/E
36.05xvs Biotechnology peers
Price to Sales (TTM)
4.88xvs Biotechnology peers
Price to Book (MRQ)
7.38xvs Biotechnology peers
Enterprise to Revenue
4.25xvs Biotechnology peers
Enterprise to EBITDA
-46.41xvs Biotechnology peers
Gross Margin
94.20%vs Biotechnology peers
Profit Margin
-9.02%vs Biotechnology peers
Operating Margin
-3.78%vs Biotechnology peers
Return on Assets (TTM)
-5.87%vs Biotechnology peers
Return on Equity (TTM)
-13.96%vs Biotechnology peers
Revenue (TTM)
535.08MUSDvs all stocks (USD)
Revenue per Share (TTM)
12.54USDUpdated Jul 19, 2026Quarterly Revenue Growth
106.90%vs Biotechnology peers
Gross Profit (TTM)
427.95MUSDvs all stocks (USD)
EBITDA (TTM)
-49.02MUSDvs all stocks (USD)
Net Income (TTM)
-48.27MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
106.87%vs Biotechnology peers
Operating Cash Flow (TTM)
-16.45MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-21.27MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
451.36MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
30.68MUSDFY2025 · Dec 31, 2025Gross Profit
420.68MUSDFY2025 · Dec 31, 2025Operating Income
-70.97MUSDvs all stocks (USD)
Pre-tax Income
-64.36MUSDFY2025 · Dec 31, 2025Income Tax Expense
2.06MUSDFY2025 · Dec 31, 2025Net Income
-66.42MUSDFY2025 · Dec 31, 2025EBIT
-56.02MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-54.20MUSDFY2025 · Dec 31, 2025Research & Development
64.32MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
427.32MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
15.75MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
8.34MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.59USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.59USDFY2025 · Dec 31, 2025Basic Shares Outstanding
41.78MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
41.78MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-66.42MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-10.64MUSDFY2025 · Dec 31, 2025Free Cash Flow
-20.50MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
186.20MUSDFY2025 · Dec 31, 2025Interest Paid
8.34MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-66.42MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.82MUSDFY2025 · Dec 31, 2025Stock-based Compensation
41.72MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.27MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-39.05MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
6.91MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
43.11MUSDFY2025 · Dec 31, 2025Capital Expenditures
-9.86MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-394.06MUSDFY2025 · Dec 31, 2025Sale of Investments
361.80MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-42.12MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
134.77MUSDFY2025 · Dec 31, 2025Shares Outstanding
43.02MSharesUpdated Jul 19, 2026Float Shares
32.11MSharesUpdated Jul 19, 2026Shares Short
5.89MSharesUpdated Jul 19, 2026Short Ratio
7.85daysvs all stocks
Short % of Shares Outstanding
14.15%vs all stocks
% Held by Insiders
3.06%vs all stocks
% Held by Institutions
109.98%vs all stocks
Total Cash (MRQ)
388.73MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
9.04USDUpdated Jul 19, 2026Total Debt (MRQ)
88.68MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.2541xvs Biotechnology peers
Current Ratio (MRQ)
3.74xvs Biotechnology peers
Book Value per Share (MRQ)
8.11USDUpdated Jul 19, 2026Total Assets
562.16MUSDvs all stocks (USD)
Total Current Assets
522.78MUSDFY2025 · Dec 31, 2025Total Liabilities
218.73MUSDFY2025 · Dec 31, 2025Total Non-current Assets
39.38MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
83.04MUSDFY2025 · Dec 31, 2025Total Current Liabilities
135.69MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
183.64MUSDFY2025 · Dec 31, 2025Other Short-term Investments
233.63MUSDFY2025 · Dec 31, 2025Accounts Receivable
85.06MUSDFY2025 · Dec 31, 2025Inventory
4.37MUSDFY2025 · Dec 31, 2025Accounts Payable
16.39MUSDFY2025 · Dec 31, 2025Other Current Liabilities
22.18MUSDFY2025 · Dec 31, 2025Long-term Debt
72.44MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
10.60MUSDFY2025 · Dec 31, 2025Common Stock (Book)
6.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-426.63MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
343.43MUSDvs all stocks (USD)
52-Week Low
38.51USDUpdated Jul 19, 202652-Week High
85.25USDUpdated Jul 19, 202652-Week Change
41.89%vs all stocks
Beta
0.4990xvs all stocks
50-Day MA
61.99USDUpdated Jul 19, 2026200-Day MA
69.03USDUpdated Jul 19, 2026Avg 10-Day Volume
1.62MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.13MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.11USDUpdated Jul 19, 2026Other Income / Expense
-202.00KUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.94Profit Margin: -0.09
Financial Health
Altman Z-Score 7.4: safe zoneNotable
Altman Z-Score: 7.40
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.61B, above the global median of $1.15BNotable
Market cap (USD): 2,611,318,462Global Median: 1,146,734,693.424
Revenue is $535.08M, above the global median of $520.53MNotable
Revenue (USD): 535,079,008Global Median: 520,528,949.311
Companies that share the same coordination system — how they create, deliver, or capture value.
Sellas Life Sciences Group Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
MicroPort Scientific Corporation
Tier 1ProductionApproval-Gated PipelineRule
Sinocelltech Group Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
AtaiBeckley Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guangzhou Innogen Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
TransMedics Group Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Kodiak Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Maravai Lifesciences Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRule
GN Store Nord A/S
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Buchang Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
CIE Automotive India Ltd.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated
Avery Dennison Corporation
1 interpretationIndustry-Benchmarked ROA and Margin Elevated
Prakash Industries Ltd.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated